HepaSphere(TM) Microsphere Initial European Clinical Experience to Be Presented at the International Symposium on Endovascular Therapy.

ROCKLAND, Mass. & ROISSY, France -- BioSphere Medical (NASDAQ: BSMD) (or "the Company") announced today that Dr. Mark Ryan, Consultant, Interventional Radiologist, Department of Radiology, St. James Hospital and Trinity College Dublin, will present "HepaSphere: A new Embolic for the Treatment of Liver Cancer," at the International Symposium on Endovascular Therapy on January 25, 2006 in Miami, Florida. Dr. Ryan's presentation will focus on HepaSphere Microsphere product attributes, animal data, early clinical experience, and the HepaSphere patient registry in Europe.

Recently, physicians in Europe have utilized the Company's proprietary HepaSphere Microspheres in treatment protocols for patients with primary liver cancer. These initial clinical cases follow the September 2005 introduction of HepaSphere Microspheres to European interventional radiologists at the meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). The Company has CE Mark approval in Europe for HepaSphere Microspheres for the embolization of liver tumors.

Richard Faleschini, president and chief executive officer of BioSphere Medical, commented, "Although early, we are pleased with the initial responses we have received from the European medical community regarding the use of HepaSphere Microspheres in the treatment of liver cancer. The rising incidence of primary liver cancer in Europe mirrors its growth around the world, where an estimated 600,000 patients are afflicted. We expect HepaSphere Microspheres will provide physicians flexibility and additional options in treating the large number of patients with liver cancer, which we believe will drive market acceptance."

HepaSphere Microspheres are designed to embolize hypervascularized tumors via a minimally invasive, catheter-based procedure. The purpose of the procedure is to occlude the blood vessels feeding the tumor, causing tumor infarction.

Gary Saxton, executive vice president and chief operating officer of BioSphere, added, "We are encouraged by the initial experience that European interventional radiologists are having with HepaSphere Microspheres for use in the treatment of liver cancer. Its ease of use and handling characteristics appear to be favorable and fit well within existing embolization protocols."

BioSphere filed a 510(k) notification in the third quarter of 2005 with the U.S. Food and Drug Administration, or FDA, seeking regulatory approval for use of the product in the United States for embolization of hypervascularized tumors and peripheral arteriovenous malformations. The Company expects marketing clearance in the United States in the first half of 2006.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, pioneers and commercializes minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments.

BioSphere Medical has received clearance in many countries, including the United States, Canada, Australia, the European Community and Latin America, which allow the Company to sell its products for use in general embolization procedures, including uterine fibroid embolization. The terms uterine fibroid embolization (UFE) and uterine artery embolization (UAE) are generally used interchangeably in the literature. The most common side effect of UFE is "post-embolization syndrome," a collection of symptoms including abdominal pain, discomfort, low-grade fever and nausea. UFE is currently contraindicated for women who are, or who intend to become, pregnant, because the effects of UFE on the ability of a woman to conceive, and to carry a fetus to term, have not been determined.

Cautionary Statement Regarding Forward-Looking Statements - This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the Company's expectations with regard to market acceptance and market penetration for its HepaSphere Microsphere product, expectations as to the percentage of cases in which the product could be used and the expected receipt and timing of marketing approval from the FDA regarding the Company's HepaSphere product. The Company uses words such as "plans," "seeks," "projects," "believes," "may," "anticipates," "estimates," "should" and similar expressions to identify these forward-looking statements. These statements are subject to risks and uncertainties and are based upon the Company's beliefs and assumptions. There are a number of important factors that may affect the Company's actual performance and results and the accuracy of its forward-looking statements, many of which are beyond the Company's control and are difficult to predict. These important factors include, without limitation, risks relating to: the failure of the Company and its distributors to successfully market and sell the Company's products; the failure of the Company to achieve or maintain necessary regulatory approvals, either in the United States or internationally, with respect to the manufacture and sale of its products and product candidates; the failure of the Company to successfully develop, commercialize and achieve widespread market acceptance of its products, including, without limitation, widespread market acceptance of its lead product, Embosphere(R) Microspheres for the treatment of UFE and its HepaSphere Microspheres product for the treatment of liver cancer; risks relating to the Company's ability to obtain and maintain patent and other proprietary protection for its products and product candidates; the absence of or delays and cancellations of, product orders; delays, difficulties or unanticipated costs in the introduction of new products; competitive pressures; the inability of the Company to raise additional funds in the near term to finance the development, marketing, and sales of its products; and general economic and market conditions, as well as the risk factors described in the section titled "Factors That May Affect Future Results" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company anticipates that subsequent events and developments may cause its forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances after the date of this press release.